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Front cover image: Integrated view of SHP 
as a central transcriptional coregulator in diverse 
physiological pathways in the liver. Activation 
pathways are shown as broken blue arrows and 
inhibitory pathways are shown as broken red 
lines. FA, fatty acid; TG, triglyceride; VLDL, very 
low density lipoprotein; CYP7A1, cytochrome 
P450 enzyme cholesterol 7α-hydroxylase; G6P, 
glucose-6-phosphatase; HNF-4α, hepatocyte 
nuclear factor 4 α; JNK, c-jun N-terminal 
kinase; LRH-1, liver receptor homolog-1; LXR, 
liver X receptor; MTP, microsomal triglyceride 
transfer protein; PEPCK, phosphoenolpyruvate 
carboxykinase; PPARγ, peroxisome proliferator-
activated receptor γ; SHP, small heterodimer 
partner; SREBP-1c, sterol regulatory element-
binding protein-1c; WAT, white adipose tissue; 
and BAT, brown adipose tissue. See Zhang et al., 
Volume 1812, Issue 8, Pages 893-908.
